title: The effect of postoperative TACE on prognosis of HCC with microscopic venous invasion.
abstract: OBJECTIVE
  The aim of this study was to evaluate the clinical efficacy of postoperative adjuvant transcatheter arterial chemoembolization (TACE) on hepatocellular carcinoma (HCC) with microscopic venous invasion.
  
  
  METHODS
  Data from 76 patients with HCC who underwent hepatectomy with or without postoperative adjuvant TACE between July 2005 and August 2010 were retrospectively reviewed. Kaplan-Meier method was used to compare survival between the groups and prognostic factors were evaluated by Cox proportional hazard model.
  
  
  RESULTS
  The 1-, 3- and 5-year disease- free survival rates were 76.3%, 44.5% and 31.8%, respectively, for the adjuvant TACE group (35 patients) and 60.1%, 39.3% and 21.5%, respectively, for the control group (41 patients). The 1-, 3- and 5-year overall survival rates were 88.6%, 67.2% and 42.3%, respectively, for the TACE group and 77.5%, 58.0% and 40.5%, respectively, for the control group. Although improving trends of both disease-free survival and overall survival were observed in adjuvant TACE group, there was no significant difference between the two groups (p>0.05). Cox regression analysis revealed that tumor size and differentiation were significant independent prognostic factors.
  
  
  CONCLUSIONS
  Postoperative adjuvant TACE may improve 1, 3 and 5 year disease-free and overall survival rates of HCC patients with microscopic venous invasion but no statistical significance was found. It can be used as a preventative treatment but not a routine procedure for such patients.
authors.affiliation: Division of Liver Transplantation, West China Hospital of Sichuan University, Sichuan Province, China.
authors.forename: Li
authors.initials: L
authors.lastname: Ke-Wei
authors.forename: Wen
authors.initials: W
authors.lastname: Tian-Fu
authors.forename: Li
authors.initials: L
authors.lastname: Xi
authors.forename: Yan
authors.initials: Y
authors.lastname: Lü-Nan
authors.forename: Li
authors.initials: L
authors.lastname: Bo
authors.forename: Zeng
authors.initials: Z
authors.lastname: Yong
authors.forename: Lu
authors.initials: L
authors.lastname: Wu-Sheng
authors.forename: Wang
authors.initials: W
authors.lastname: Wen-Tao
authors.forename: Xu
authors.initials: X
authors.lastname: Ming-Qing
authors.forename: Yang
authors.initials: Y
authors.lastname: Jia-Yin
authors.forename: Ma
authors.initials: M
authors.lastname: Yu-Kui
authors.forename: Chen
authors.initials: C
authors.lastname: Zhe-Yu
mesh_terms: D000328:Adult; D006528:Carcinoma, Hepatocellular / Q000401:mortality / Q000473:pathology / Q000628:therapy*; D016461:Chemoembolization, Therapeutic; D017024:Chemotherapy, Adjuvant; D016009:Chi-Square Distribution; D002681:China; D018572:Disease-Free Survival; D005260:Female; D006498:Hepatectomy; D006801:Humans; D053208:Kaplan-Meier Estimate; D008113:Liver Neoplasms / Q000401:mortality / Q000473:pathology / Q000628:therapy*; D008297:Male; D008875:Middle Aged; D015999:Multivariate Analysis; D009361:Neoplasm Invasiveness; D016016:Proportional Hazards Models; D012189:Retrospective Studies; D018570:Risk Assessment; D012307:Risk Factors; D013997:Time Factors; D016896:Treatment Outcome; D014680:Veins / Q000473:pathology*